Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 597

1.

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

Angenendt L, Röllig C, Montesinos P, Martínez-Cuadrón D, Barragan E, García R, Botella C, Martínez P, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, Höglund M, Lehmann S, Recher C, Pigneux A, Bertoli S, Dumas PY, Dombret H, Preudhomme C, Micol JB, Terré C, Ráčil Z, Novák J, Žák P, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Exeler R, Wagenführ L, Stölzel F, Thiede C, Stelljes M, Lenz G, Mikesch JH, Serve H, Ehninger G, Berdel WE, Kramer M, Krug U, Schliemann C.

J Clin Oncol. 2019 Oct 10;37(29):2632-2642. doi: 10.1200/JCO.19.00416. Epub 2019 Aug 20.

PMID:
31430225
2.

EZH2 mutations and impact on clinical outcome - an analysis in 1604 patients with newly diagnosed acute myeloid leukemia.

Stasik S, Middeke JM, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause S, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Bornhäuser M, Schetelig J, Thiede C.

Haematologica. 2019 Aug 14. pii: haematol.2019.222323. doi: 10.3324/haematol.2019.222323. [Epub ahead of print]

3.

The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.

Angenendt L, Bormann E, Pabst C, Alla V, Görlich D, Braun L, Dohlich K, Schwöppe C, Bohlander SK, Arteaga MF, Wethmar K, Hartmann W, Angenendt A, Kessler T, Mesters RM, Stelljes M, Rothenberg-Thurley M, Spiekermann K, Hébert J, Sauvageau G, Valk PJM, Löwenberg B, Serve H, Müller-Tidow C, Lenz G, Wörmann BJ, Sauerland MC, Hiddemann W, Berdel WE, Krug U, Metzeler KH, Mikesch JH, Herold T, Schliemann C.

Leukemia. 2019 Jun 10. doi: 10.1038/s41375-019-0505-x. [Epub ahead of print]

PMID:
31182782
4.

Oral targeted agent versus chemotherapy in acute myeloid leukaemia.

Röllig C, Berdel WE.

Lancet Oncol. 2019 Jul;20(7):896-898. doi: 10.1016/S1470-2045(19)30305-5. Epub 2019 Jun 4. No abstract available.

PMID:
31175002
5.

Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer.

Schulze AB, Evers G, Kerkhoff A, Mohr M, Schliemann C, Berdel WE, Schmidt LH.

Cancers (Basel). 2019 May 17;11(5). pii: E690. doi: 10.3390/cancers11050690. Review.

6.

Noncaseating granulomatous diseases in germ cell cancer patients-A single-center experience.

Schmidt LH, Huss S, Schuelke C, Schulze A, Evers G, Schliemann C, Hansmeier A, Schilling B, Lauterbach B, Barth P, Wiebe K, Goerlich D, Berdel WE, Puehse G, Mohr M.

Urol Oncol. 2019 Aug;37(8):531.e17-531.e25. doi: 10.1016/j.urolonc.2019.03.010. Epub 2019 Apr 30.

PMID:
31053525
7.

Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).

Kessler T, Koschmieder S, Schliemann C, Crysandt M, Mikesch JH, von Stillfried S, Stelljes M, Pohlen M, Lenz G, Kirsch A, Vehring K, Wardelmann E, Hartmann W, Bormann E, Gerss J, Brümmendorf TH, Müller-Tidow C, Berdel WE.

Ann Hematol. 2019 Jun;98(6):1393-1401. doi: 10.1007/s00277-019-03651-9. Epub 2019 Mar 21.

PMID:
30903275
8.

Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL).

Reinartz G, Pyra RP, Lenz G, Liersch R, Stüben G, Micke O, Willborn K, Hess CF, Probst A, Fietkau R, Jany R, Schultze J, Rübe C, Hirt C, Fischbach W, Bentz M, Daum S, Pott C, Tiemann M, Möller P, Neubauer A, Wilhelm M, Willich N, Berdel WE, Eich HT.

Strahlenther Onkol. 2019 Jun;195(6):544-557. doi: 10.1007/s00066-019-01446-5. Epub 2019 Mar 11.

PMID:
30859254
9.

The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches.

Gerwing M, Herrmann K, Helfen A, Schliemann C, Berdel WE, Eisenblätter M, Wildgruber M.

Nat Rev Clin Oncol. 2019 Jul;16(7):442-458. doi: 10.1038/s41571-019-0169-5. Review.

PMID:
30718844
10.

Gadofosveset-enhanced MRI as simple surrogate parameter for real-time evaluation of the initial tumour vessel infarction by retargeted tissue factor tTF-NGR.

Höink A, Persigehl T, Kwiecien R, Balthasar M, Mesters R, Berdel W, Heindel W, Bremer C, Schwöppe C.

Oncol Lett. 2019 Jan;17(1):270-280. doi: 10.3892/ol.2018.9638. Epub 2018 Oct 29.

11.

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M.

Haematologica. 2019 May;104(5):955-962. doi: 10.3324/haematol.2018.206797. Epub 2018 Dec 4.

12.

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA.

Konstandin NP, Pastore F, Herold T, Dufour A, Rothenberg-Thurley M, Hinrichsen T, Ksienzyk B, Tschuri S, Schneider S, Hoster E, Berdel WE, Woermann BJ, Sauerland MC, Braess J, Bohlander SK, Klein HG, Hiddemann W, Metzeler KH, Spiekermann K.

Blood Adv. 2018 Oct 23;2(20):2724-2731. doi: 10.1182/bloodadvances.2018016840.

13.

Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.

Kessler T, Baumeier A, Brand C, Grau M, Angenendt L, Harrach S, Stalmann U, Schmidt LH, Gosheger G, Hardes J, Andreou D, Dreischalück J, Lenz G, Wardelmann E, Mesters RM, Schwöppe C, Berdel WE, Hartmann W, Schliemann C.

Transl Oncol. 2018 Dec;11(6):1271-1282. doi: 10.1016/j.tranon.2018.08.004. Epub 2018 Aug 17.

14.

Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia.

Hornung R, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Amler S, Sauerland MC, Berdel WE, Wörmann BJ, Bohlander SK, Braess J, Hiddemann W, Lehmann S, Mareschal S, Spiekermann K, Metzeler KH, Herold T, Boulesteix AL.

Sci Rep. 2018 Jul 26;8(1):11293. doi: 10.1038/s41598-018-29593-2.

15.

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia.

Schranz K, Hubmann M, Harin E, Vosberg S, Herold T, Metzeler KH, Rothenberg-Thurley M, Janke H, Bräundl K, Ksienzyk B, Batcha AMN, Schaaf S, Schneider S, Bohlander SK, Görlich D, Berdel WE, Wörmann BJ, Braess J, Krebs S, Hiddemann W, Mansmann U, Spiekermann K, Greif PA.

Oncotarget. 2018 Jul 10;9(53):30128-30145. doi: 10.18632/oncotarget.25729. eCollection 2018 Jul 10.

16.

Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth.

Bäumer N, Rehkämper J, Appel N, Terheyden L, Hartmann W, Wardelmann E, Buchholz F, Müller-Tidow C, Berdel WE, Bäumer S.

PLoS One. 2018 Jul 12;13(7):e0200163. doi: 10.1371/journal.pone.0200163. eCollection 2018.

17.

90 Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience.

Spukti EU, Schmidt LH, Schulze A, Schliemann C, Görlich D, Wardelmann E, Hartmann W, Lenz G, Berdel WE, Kerkhoff A.

Eur J Haematol. 2018 Oct;101(4):514-521. doi: 10.1111/ejh.13138. Epub 2018 Sep 3.

PMID:
29993147
18.

Stromal collagen type VI associates with features of malignancy and predicts poor prognosis in salivary gland cancer.

Angenendt L, Mikesch JH, Görlich D, Busch A, Arnhold I, Rudack C, Hartmann W, Wardelmann E, Berdel WE, Stenner M, Schliemann C, Grünewald I.

Cell Oncol (Dordr). 2018 Oct;41(5):517-525. doi: 10.1007/s13402-018-0389-1. Epub 2018 Jun 15.

PMID:
29949051
19.

Treating Anemia in the Preanesthesia Assessment Clinic: Results of a Retrospective Evaluation.

Ellermann I, Bueckmann A, Eveslage M, Buddendick H, Latal T, Niehoff D, Geissler RG, Hempel G, Kerkhoff A, Berdel WE, Roeder N, Van Aken HK, Zarbock A, Steinbicker AU.

Anesth Analg. 2018 Nov;127(5):1202-1210. doi: 10.1213/ANE.0000000000003583.

PMID:
29944518
20.

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.

Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, Konstandin NP, Goerlich D, Krug U, Faldum A, Berdel WE, Wörmann B, Braess J, Schneider S, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Metzeler KH.

Haematologica. 2018 Nov;103(11):1853-1861. doi: 10.3324/haematol.2018.191536. Epub 2018 Jun 14.

21.

AAA+ ATPases Reptin and Pontin as potential diagnostic and prognostic biomarkers in salivary gland cancer - a short report.

Mikesch JH, Hartmann W, Angenendt L, Huber O, Schliemann C, Arteaga MF, Wardelmann E, Rudack C, Berdel WE, Stenner M, Grünewald I.

Cell Oncol (Dordr). 2018 Aug;41(4):455-462. doi: 10.1007/s13402-018-0382-8. Epub 2018 Jun 5.

PMID:
29873033
22.

Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer.

Mikesch JH, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Köhler G, Lenz G, Müller-Tidow C, Berdel WE, Arteaga MF.

Eur Respir J. 2018 Jul 11;52(1). pii: 1701637. doi: 10.1183/13993003.01637-2017. Print 2018 Jul.

PMID:
29853494
23.

Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases.

Schliemann C, Kerkhoff A, Hesse P, Bröckling S, Hardes J, Streitbürger A, Andreou D, Gosheger G, Elges S, Wardelmann E, Hartmann W, Mesters R, Lenz G, Willich N, Kriz J, Eich H, Berdel WE, Kessler T.

PLoS One. 2018 May 22;13(5):e0197315. doi: 10.1371/journal.pone.0197315. eCollection 2018.

24.

Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.

Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A; PETAL Trial Investigators.

J Clin Oncol. 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May 11.

PMID:
29750632
25.

Exacerbation of mycosis fungoides leading to the diagnosis of chronic myelomonocytic leukemia.

Moritz RKC, Metze D, Wiebe S, Kerkhoff A, Berdel WE, Weishaupt C.

JAAD Case Rep. 2018 Mar 6;4(3):270-273. doi: 10.1016/j.jdcr.2017.09.023. eCollection 2018 Apr. No abstract available.

26.

Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial.

Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, Stadler M, Schäfer-Eckart K, Bätzel M, Eich H, Stuschke M, Engenhart-Cabillic R, Krause M, Dreger P, Neubauer A, Ehninger G, Beelen D, Berdel WE, Siepmann T, Stelljes M, Bornhäuser M.

Lancet Haematol. 2018 Apr;5(4):e161-e169. doi: 10.1016/S2352-3026(18)30022-X. Epub 2018 Mar 14.

PMID:
29550384
27.

High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.

Steckel NK, Groth C, Mikesch JH, Trenschel R, Ottinger H, Kordelas L, Mueller-Tidow C, Schliemann C, Reicherts C, Albring JC, Silling G, Schmidt E, Berdel WE, Lenz G, Ditschkowski M, Beelen DW, Stelljes M.

Br J Haematol. 2018 Mar;180(6):840-853. doi: 10.1111/bjh.15137. Epub 2018 Feb 21.

PMID:
29468631
28.

Loss-of-function uORF mutations in human malignancies.

Schulz J, Mah N, Neuenschwander M, Kischka T, Ratei R, Schlag PM, Castaños-Vélez E, Fichtner I, Tunn PU, Denkert C, Klaas O, Berdel WE, von Kries JP, Makalowski W, Andrade-Navarro MA, Leutz A, Wethmar K.

Sci Rep. 2018 Feb 5;8(1):2395. doi: 10.1038/s41598-018-19201-8.

29.

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.

Röllig C, Kramer M, Gabrecht M, Hänel M, Herbst R, Kaiser U, Schmitz N, Kullmer J, Fetscher S, Link H, Mantovani-Löffler L, Krümpelmann U, Neuhaus T, Heits F, Einsele H, Ritter B, Bornhäuser M, Schetelig J, Thiede C, Mohr B, Schaich M, Platzbecker U, Schäfer-Eckart K, Krämer A, Berdel WE, Serve H, Ehninger G, Schuler US; Study Alliance Leukemia (SAL).

Ann Oncol. 2018 Apr 1;29(4):973-978. doi: 10.1093/annonc/mdy030.

PMID:
29390048
30.

Alloantigen expression on malignant cells and healthy host tissue influences graft-versus-tumor reactions after allogeneic hematopoietic stem cell transplantation.

Robert S, Albring JC, Frebel K, Opitz C, Urh J, Wolf C, Heinrich C, Berdel WE, Stelljes M.

Bone Marrow Transplant. 2018 Jul;53(7):807-819. doi: 10.1038/s41409-017-0071-7. Epub 2018 Jan 23.

PMID:
29362503
31.

Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients.

Greif PA, Hartmann L, Vosberg S, Stief SM, Mattes R, Hellmann I, Metzeler KH, Herold T, Bamopoulos SA, Kerbs P, Jurinovic V, Schumacher D, Pastore F, Bräundl K, Zellmeier E, Ksienzyk B, Konstandin NP, Schneider S, Graf A, Krebs S, Blum H, Neumann M, Baldus CD, Bohlander SK, Wolf S, Görlich D, Berdel WE, Wörmann BJ, Hiddemann W, Spiekermann K.

Clin Cancer Res. 2018 Apr 1;24(7):1716-1726. doi: 10.1158/1078-0432.CCR-17-2344. Epub 2018 Jan 12.

32.

Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction.

Pohlen M, Thoennissen NH, Braess J, Thudium J, Schmid C, Kochanek M, Kreuzer KA, Lebiedz P, Görlich D, Gerth HU, Rohde C, Kessler T, Müller-Tidow C, Stelljes M, Hullerman C, Büchner T, Schlimok G, Hallek M, Waltenberger J, Hiddemann W, Berdel WE, Heilmeier B, Krug U.

PLoS One. 2018 Jan 2;13(1):e0190802. doi: 10.1371/journal.pone.0190802. eCollection 2018.

33.

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.

Herold T, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Ksienzyk B, Hartmann L, Greif PA, Phillippou-Massier J, Krebs S, Blum H, Amler S, Schneider S, Konstandin N, Sauerland MC, Görlich D, Berdel WE, Wörmann BJ, Tischer J, Subklewe M, Bohlander SK, Braess J, Hiddemann W, Metzeler KH, Mansmann U, Spiekermann K.

Haematologica. 2018 Mar;103(3):456-465. doi: 10.3324/haematol.2017.178442. Epub 2017 Dec 14.

34.

EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.

Ferrari S, Bielack SS, Smeland S, Longhi A, Egerer G, Sundby Hall K, Donati D, Kevric M, Brosjö O, Comandone A, Werner M, Monge O, Palmerini E, Berdel WE, Bjerkehagen B, Paioli A, Lorenzen S, Eriksson M, Gambarotti M, Tunn PU, Jebsen NL, Cesari M, von Kalle T, Ferraresi V, Schwarz R, Bertulli R, Kasparek AK, Grignani G, Krasniqi F, Sorg B, Hecker-Nolting S, Picci P, Reichardt P.

Tumori. 2018 Jan-Feb;104(1):30-36. doi: 10.5301/tj.5000696.

PMID:
29218692
35.

Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.

Lengfelder E, Görlich D, Nowak D, Spiekermann K, Haferlach C, Krug U, Kreuzer KA, Braess J, Schliemann C, Lindemann HW, Horst HA, Schiel X, Flasshove M, Hecht A, Schnittger S, Schneider S, Wörmann B, Hofmann WK, Berdel WE, Bormann E, Sauerland C, Büchner T, Hiddemann W; German Acute Myeloid Leukemia Cooperative Group (AMLCG).

Eur J Haematol. 2018 Feb;100(2):154-162. doi: 10.1111/ejh.12994. Epub 2017 Dec 4.

PMID:
29114972
36.

CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.

Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M, Görlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Berdel WE, Schwöppe C, Hartmann W.

Lung Cancer. 2017 Nov;113:121-127. doi: 10.1016/j.lungcan.2017.09.013. Epub 2017 Sep 22.

PMID:
29110838
37.

Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.

Schmidt LH, Heitkötter B, Schulze AB, Schliemann C, Steinestel K, Trautmann M, Marra A, Hillejan L, Mohr M, Evers G, Wardelmann E, Rahbar K, Görlich D, Lenz G, Berdel WE, Hartmann W, Wiewrodt R, Huss S.

PLoS One. 2017 Oct 27;12(10):e0186280. doi: 10.1371/journal.pone.0186280. eCollection 2017.

38.

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.

Schultheis B, Reuter D, Ebert MP, Siveke J, Kerkhoff A, Berdel WE, Hofheinz R, Behringer DM, Schmidt WE, Goker E, De Dosso S, Kneba M, Yalcin S, Overkamp F, Schlegel F, Dommach M, Rohrberg R, Steinmetz T, Bulitta M, Strumberg D.

Ann Oncol. 2017 Oct 1;28(10):2429-2435. doi: 10.1093/annonc/mdx343.

PMID:
28961832
39.

Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.

Heidrich K, Thiede C, Schäfer-Eckart K, Schmitz N, Aulitzky WE, Krämer A, Rösler W, Hänel M, Einsele H, Baldus CD, Trappe RU, Stölzel F, Middeke JM, Röllig C, Taube F, Kramer M, Serve H, Berdel WE, Ehninger G, Bornhäuser M, Schetelig J; Study Alliance Leukemia (SAL).

Ann Oncol. 2017 Nov 1;28(11):2793-2798. doi: 10.1093/annonc/mdx500.

PMID:
28945881
40.

Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.

Kropff M, Vogel M, Bisping G, Schlag R, Weide R, Knauf W, Fiechtner H, Kojouharoff G, Kremers S, Berdel WE.

Ann Hematol. 2017 Nov;96(11):1857-1866. doi: 10.1007/s00277-017-3065-z. Epub 2017 Sep 14.

PMID:
28905189
41.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

42.

Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Aug 9;12(8):e0183201. doi: 10.1371/journal.pone.0183201. eCollection 2017.

43.

Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.

Meißner T, Mark A, Williams C, Berdel WE, Wiebe S, Kerkhoff A, Wardelmann E, Gaiser T, Müller-Tidow C, Rosenstiel P, Arnold N, Leyland-Jones B, Franke A, Stanulla M, Forster M.

Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001677. doi: 10.1101/mcs.a001677. Print 2017 Jul.

44.

A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.

Beck D, Thoms JAI, Palu C, Herold T, Shah A, Olivier J, Boelen L, Huang Y, Chacon D, Brown A, Babic M, Hahn C, Perugini M, Zhou X, Huntly BJ, Schwarzer A, Klusmann JH, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Bohlander SK, To LB, Scott HS, Lewis ID, D'Andrea RJ, Wong JWH, Pimanda JE.

Leukemia. 2018 Feb;32(2):263-272. doi: 10.1038/leu.2017.210. Epub 2017 Jul 4.

PMID:
28674423
45.

An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Angenendt L, Reuter S, Kentrup D, Benk AS, Neumann F, Hüve J, Martens AC, Schwöppe C, Kessler T, Schmidt LH, Sauer T, Brand C, Mikesch JH, Lenz G, Mesters RM, Müller-Tidow C, Hartmann W, Wardelmann E, Neri D, Berdel WE, Roesli C, Schliemann C.

Leukemia. 2018 Feb;32(2):510-519. doi: 10.1038/leu.2017.208. Epub 2017 Jun 30.

PMID:
28663580
46.

AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia.

Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Köhn M, Misiak D, Bäumer N, Cui C, Göllner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Hüttelmaier S, Müller-Tidow C.

Nat Cell Biol. 2017 Jul;19(7):844-855. doi: 10.1038/ncb3563. Epub 2017 Jun 26.

PMID:
28650479
47.

Development of quality of life in patients undergoing allogeneic stem cell transplantation with regard to anxiety, depression and resilience.

Schumacher A, Sauerland C, Silling G, Berdel WE, Stelljes M, Koch R.

Bone Marrow Transplant. 2017 Sep;52(9):1334-1337. doi: 10.1038/bmt.2017.123. Epub 2017 Jun 26. No abstract available.

PMID:
28650452
48.

Therapy of older persons with acute myeloid leukaemia.

Krug U, Gale RP, Berdel WE, Müller-Tidow C, Stelljes M, Metzeler K, Sauerland MC, Hiddemann W, Büchner T.

Leuk Res. 2017 Sep;60:1-10. doi: 10.1016/j.leukres.2017.05.020. Epub 2017 Jun 1. Review.

PMID:
28618329
49.

Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Jun 12;12(6):e0177146. doi: 10.1371/journal.pone.0177146. eCollection 2017. Erratum in: PLoS One. 2017 Aug 9;12 (8):e0183201.

50.

Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.

Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J Jr.

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788a. No abstract available.

PMID:
28586337

Supplemental Content

Loading ...
Support Center